Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 years after diagnosis. We describe a new concept for treatment of the disease using vasoactive intestinal peptide, a neuropeptide primarily functioning as a neurotransmitter that acts as a potent systemic and pulmonary vasodilator. Our rationale is based on the finding of a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by radioimmunoassay and immunohistochemistry. The relevance of this finding is underlined by an upregulation of corresponding receptor sites as shown by Northern blot analysis, Western blot analysis, and immunological techniques. Consequently, the substitution with the hormone results in substantial improvement of hemodynamic and prognostic parameters of the disease without side effects. It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation. Our data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS
Scatchard, G. (1949) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1949.tb27297.x · Cited by 19,778
Psychophysical bases of perceived exertion
BORG, G. A. V. (1982) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-198205000-00012 · Cited by 16,580
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,401
Primary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., & Stewart, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282402 · Cited by 1,842
Primary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Giaid, A., & Saleh, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507273330403 · Cited by 1,369
Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,187
Cited by
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Cellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Writing Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010) · Circulation · doi:10.1161/circulationaha.108.847707 · Cited by 485
VPAC and PAC receptors: From ligands to function
Dickson, L., & Finlayson, K. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.006 · Cited by 379
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
Pulmonary arterial hypertension
Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, E., Price, L. C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-97 · Cited by 314
Pulmonary Arterial Hypertension
Chin, K. M., & Rubin, L. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.024 · Cited by 309
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Current pharmacological treatments for COVID‐19: What's next?
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C., Zoccoli, A., Berrino, L., Racagni, G., Rossi, F., & Capuano, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15072 · Cited by 283
Pathogenic mechanisms of pulmonary arterial hypertension
Chan, S. Y., & Loscalzo, J. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.09.006 · Cited by 265
Thyroid hormone and blood pressure regulation
Danzi, S., & Klein, I. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0060-7 · Cited by 261
“Recent data suggest that primary pulmonary hypertension might be associated with a deficiency of a neuropeptide, vasoactive intestinal peptide (VIP) [ 80 ].”
Background
Metadata
- Authors
- Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G.-C., Hamilton, G., Novotny, C., Burian, B., & Block, L.-H.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-01
- Volume
- 111
- Issue
- 9
- Pages
- 1339-1346
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2160832358
- Cited by
- 352
- References
- 22
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.